ER 35794Alternative Names: ER-35794
Latest Information Update: 17 Nov 2006
At a glance
- Originator Eisai Co Ltd
- Class Antineoplastics; Retinoids; Small molecules
- Mechanism of Action Retinoid X receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 May 2001 No Development Reported for Cancer in Japan (Unknown route)
- 03 Dec 1997 Preclinical development for Cancer in Japan (Unknown route)